Scope
This House summary selects common assessment and treatment decisions from the EAU guideline for non-neurogenic female lower urinary tract symptoms. Distinguish storage symptoms, stress or urgency leakage, mixed incontinence and impaired emptying before choosing treatment. Patient priorities, cognitive burden, residual urine and the consequences of invasive treatment matter alongside symptom scores. Complex obstruction, fistula and reconstructive surgery require the fuller specialist pathways.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assess symptoms and identify another cause
- Take a complete history and focused examination, including sexual, bowel and neurological symptoms. Consider onward referral for pain, haematuria, recurrent infection, prior pelvic surgery/radiotherapy, continuous leakage suggesting fistula, new enuresis or suspected neurological disease. [1]
- Use a validated symptom, bother and quality-of-life questionnaire, and a bladder diary lasting at least three days, for initial assessment and follow-up of female LUTS (strong). Symptoms and their impact, not leakage alone, should guide reassessment. [1]
- Perform urinalysis initially and reassess LUTS after treating a symptomatic urinary infection. Do not routinely treat asymptomatic bacteriuria in older patients just to improve incontinence (strong). Measure residual urine by ultrasound and monitor it during treatments that can worsen emptying (strong). [1]
- Do not routinely use urodynamics for uncomplicated stress incontinence or first-line treatment of uncomplicated overactive bladder (strong). Consider it when diagnostic uncertainty or a possible change in invasive treatment justifies testing (weak). Routine urinary-tract imaging beyond residual estimation is not part of initial female-LUTS assessment. [1]
Start overactive-bladder care conservatively
- For overactive bladder, review current medicines and any new drug linked with worsening symptoms. Address associated obesity or sleep apnoea where relevant, and choose conservative treatment jointly with the patient; medication review and shared decisions are strong recommendations. [1]
- Explain that reducing caffeine can improve overactive-bladder urgency and frequency but has not been shown to improve incontinence. Encourage weight loss and its maintenance in overweight or obese patients and provide smoking-cessation support (strong); review fluid type and quantity individually (weak). [1]
- Offer bladder training first-line for adult overactive bladder or urgency incontinence, and prompted voiding when cognitive impairment limits independent toileting. Posterior tibial nerve stimulation is an option for symptom improvement (strong). [1]
Escalate overactive-bladder treatment with monitoring
- After unsuccessful conservative management, offer an anticholinergic or beta-3 agonist for overactive bladder (strong). Consider extended-release anticholinergic formulations when possible and review efficacy and adverse effects early. Dry mouth, constipation and cognitive effects should inform the choice. [1]
- Use long-term anticholinergics cautiously in older women, particularly with existing or potential cognitive dysfunction. Assess total anticholinergic burden and comorbidity before treatment (strong), and monitor mental function when starting these drugs in older patients. [1]
- For ineffective anticholinergic treatment of overactive bladder, consider dose escalation, another formulation or a beta-3 agonist alone or combined with the anticholinergic (strong). Early follow-up also applies to beta-3 treatment; do not escalate without revisiting benefit and adverse effects. [1]
- Offer bladder-wall onabotulinumtoxinA 100 U for overactive bladder/urgency incontinence refractory to conservative or drug treatment (strong). Before proceeding, explain its limited response duration, urinary-infection risk and possible prolonged need for intermittent catheterisation. [1]
- Offer sacral nerve stimulation for overactive bladder or urgency incontinence refractory to anticholinergic therapy (strong), with lifelong implant surveillance for lead displacement, malfunction and battery wear. Vaginal laser treatment for overactive bladder should remain within a properly regulated research study. [1]
Treat stress incontinence and discuss surgical choices
- For stress or mixed urinary incontinence, offer supervised intensive pelvic-floor muscle training for at least three months first-line, including older and pre/postnatal women (strong). Discuss its benefits and low adverse-event burden before invasive treatment. [1]
- For postmenopausal stress incontinence with vulvovaginal atrophy, offer vaginal oestrogen (strong). If oral conjugated equine oestrogen is associated with new or worsening stress incontinence, discuss alternative hormone replacement. The recommendation is not a general endorsement of systemic oestrogen for leakage. [1]
- Where licensed, duloxetine may be offered to selected women with stress incontinence unresponsive to other conservative care who wish to avoid invasive treatment (weak). Counsel about adverse effects and titrate both initiation and withdrawal (strong). [1]
- After conservative options including pelvic-floor training have been explored or failed, discuss the range of stress-incontinence operations through shared decision-making (strong). Options include colposuspension, autologous sling, midurethral sling and urethral bulking, each requiring its own benefits-and-risks discussion. [1]
- For a woman choosing a midurethral sling for stress incontinence, discuss mesh complications and all alternatives, follow local mesh-surgery rules, and perform cystoscopy during synthetic sling insertion to check for bladder perforation (strong). The guideline reports better long-term outcomes for retropubic than transobturator placement. [1]
- When stress-incontinence patients prefer a lower-risk procedure, explain that urethral bulking is less effective than other operations, repeat injection is likely and long-term durability and safety are uncertain (strong). Do not present it as equivalent to a durable sling or colposuspension result. [1]
- Manage complicated stress incontinence in experienced centres (strong). Recurrent leakage after surgery needs individualized evaluation, potentially including cystoscopy and multichannel urodynamics; explain that repeat surgery usually has lower effectiveness and more complications than first-line surgery (weak counselling recommendation). [1]
Separate mixed symptoms from impaired emptying
- For mixed incontinence, characterize the stress- versus urgency-predominant pattern and treat the most bothersome symptom first (weak). Offer bladder training and at least three months of supervised pelvic-floor training (strong); explain that one treatment may not resolve both components. [1]
- For women unable to empty the bladder, intermittent catheterisation with instruction in technique and risks is standard treatment (strong). Double voiding can be encouraged (weak); warn that abdominal straining may increase prolapse risk. Do not routinely use parasympathomimetics for underactive bladder. [1]
- Do not diagnose female outlet obstruction from flow measurements alone. For suspected anatomical obstruction, perform cystourethroscopy and urodynamics, preferably with videofluoroscopy (strong). For functional obstruction, pelvic-floor training should emphasize relaxation rather than simply strengthening (strong). [1]
Investigate and treat nocturia by cause
- For nocturia, take a full history including sleep disorders and use a three-day bladder diary rather than a night-only diary. When nocturia predominates, consider renal and thyroid function, HbA1c and calcium testing (strong). Refer suspected obstructive sleep apnoea for sleep-clinic assessment. [1]
- Desmopressin is offered for nocturia caused by nocturnal polyuria, with counselling about benefits and hyponatraemia risk (strong). Avoid it when baseline sodium is below normal and carefully monitor sodium in older patients. This is not a general treatment for every cause of night-time voiding. [1]
Limitations and use
- This focused summary covers common non-neurogenic female LUTS pathways. It does not provide complete protocols for neurogenic bladder, recurrent infection, pelvic-organ prolapse, urinary fistula, diverticulum or complex reconstructive surgery.
- Drug selection still requires contraindication, interaction, renal-function and local product-label checks; formulation-specific doses and full monitoring schedules are not reproduced here. Mesh availability and regulatory rules differ by jurisdiction.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Non-neurogenic female lower urinary tract symptoms
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.